Arena Pharmaceuticals, Inc.ARNA

Arena Pharmaceuticals, Inc. (ARNA): trades by Congress and the executive branch

Every trade in Arena Pharmaceuticals, Inc. that a representative, a senator, the President or a senior official disclosed since 2020, newest report first. Each is read from the filer’s periodic transaction report and linked to it.

Latest report May 17, 2021 · Source · RSS feed

Trades disclosed
13since 2020
Members
3
Purchases / sales
4 / 9
Typical days to public
28median
Public after 45 days
0of 8 dated trades by Congress

Congress trade alerts · ARNA · free

Get an email when anyone in Congress trades Arena Pharmaceuticals, Inc.

Each new disclosure of a trade in the stock by a representative, a senator, the President or a senior official, with the filing.

An email when a member of Congress or the executive branch files a trade in ARNA, with the filing. Unsubscribe in one click.

Transactions

Every ARNA trade disclosed since 2020, newest report first
MemberAssetTypeAmountTrade dateLagPublicFiling
Thomas CarperD-DESenateARNAArena Pharmaceuticals, Inc. · SpouseBuy$1K–$15KNov 20, 2020amendedMay 17Report
John YarmuthD-KYKY03ARNAArena Pharmaceuticals, Inc.Buy$1K–$15KFeb 12, 20217dFeb 19PDF
Thomas CarperD-DESenateARNAArena Pharmaceuticals, Inc. · SpouseBuy$1K–$15KNov 20, 202012dDec 2Report
John YarmuthD-KYKY03ARNAArena Pharmaceuticals, Inc.Buy$1K–$15KNov 5, 202010dNov 15PDF
Kelly LoefflerR-GASenateARNAArena Pharmaceuticals, Inc. · JointSell$15K–$50KApr 7, 202024dMay 1Report
Kelly LoefflerR-GASenateARNAArena Pharmaceuticals, Inc. · JointSell$15K–$50KFeb 26, 2020amendedMay 1Report
Kelly LoefflerR-GASenateARNAArena Pharmaceuticals, Inc. · JointSell$50K–$100KFeb 24, 2020amendedMay 1Report
Kelly LoefflerR-GASenateARNAArena Pharmaceuticals, Inc. · JointSell$50K–$100KFeb 6, 2020amendedMay 1Report
Kelly LoefflerR-GASenateARNAArena Pharmaceuticals, Inc. · JointSell$50K–$100KFeb 5, 2020amendedMay 1Report
Kelly LoefflerR-GASenateARNAArena Pharmaceuticals, Inc. · JointSell$15K–$50KFeb 26, 202034dMar 31Report
Kelly LoefflerR-GASenateARNAArena Pharmaceuticals, Inc. · JointSell$50K–$100KFeb 24, 202036dMar 31Report
Kelly LoefflerR-GASenateARNAArena Pharmaceuticals, Inc. · JointSell$50K–$100KFeb 10, 202031dMar 12Report
Kelly LoefflerR-GASenateARNAArena Pharmaceuticals, Inc. · JointSell$50K–$100KFeb 7, 202034dMar 12Report

Members who traded ARNA

MemberTradesBuysSellsLast tradedLatest report
Kelly LoefflerR-GASenate909Apr 7, 2020May 1, 2020
Thomas CarperD-DESenate220Nov 20, 2020May 17, 2021
John YarmuthD-KYKY03220Feb 12, 2021Feb 19, 2021

Source

Each trade is a line of a periodic transaction report filed under the STOCK Act, read from the report itself and linked to it. Three offices publish them, and all three are read here every hour: the House Clerk for representatives, the Senate Office of Public Records for senators, and the Office of Government Ethics for the President, the Vice President and Senate-confirmed officials (OGE Form 278-T). OGE links some officials’ reports and releases the rest on request; only linked reports are here.

The Act requires a report within 45 days of the trade; the lag counts the days from the trade to the day the report became public. Reports give each amount as a range. Amendments are marked and not counted as late; trades a later report withdrew are left out. The President’s reports and some House reports are scans of paper forms: a scanned value that does not read with certainty is shown as not read, never guessed, and the report is one click away. “Since” is the stock’s move from the trade date’s close to the latest daily close.

The same trades are in the OptimistFi MCP server’s get_congress_trades tool, by filer or by stock, for each chamber: connect it. Every House trade is free to download as CSV or JSON, and every trade here can be followed by RSS: the data.

ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.